HGH Fragment 176-191 — targeted lipolytic peptide
5 lyophilised vials × 10 mg (total 50 mg)
- Selective fat-loss: fragment 176-191 enhances lipolysis and blocks lipogenesis without raising glucose or IGF-1.
- Reconstitution: add 2 ml bacteriostatic water → 5 mg/ml; swirl gently, do not shake.
- Storage: refrigerate 2 – 8 °C once mixed; freeze-dried powder ships safely at room temperature.
- Sample research dosing: 250 – 500 µg sub-Q 1–3 × daily, 30 min pre-cardio, for 4–6 weeks.
- QC: ≥ 99 % purity (HPLC); endotoxin < 0.03 EU/mg; scratch-code authenticity on every box.
- Cold-chain packed • tamper-evident vials • discreet, tracked worldwide delivery.
⚗️ Storage & Handling
-
Store refrigerated at 2–8 °C (35–46 °F)
-
Protect from light; keep vials sealed until reconstitution
-
Maintain cold‑chain integrity during shipping
-
For research use only — not approved for human consumption outside supervised protocols
Parameter Standard Range Notes Total content 50 mg Kit format Administration Subcutaneous injection Abdomen, thigh, or upper arm Frequency Daily Often split into 1–2 injections Daily dose 250–500 mcg Commonly studied ranges Timing Morning or post workout Enhances fat‑loss response Research focus Fat metabolism, weight management Lipolysis stimulation
-
